Seltorexant

Seltorexant, developed under the code JNJ-42847922 and also referenced as MIN-202, is a potent and selective antagonist of the orexin-2 receptor, distinguishing it from dual orexin receptor antagonists that block both orexin-1 and orexin-2 ^[3][4]. Orexins are wake-promoting neuropeptides, and by targeting only the orexin-2 subtype the compound aims to promote sleep while preserving a cleaner tolerability profile ^[1][4].

The clinical program spans two linked indications. In insomnia, randomized polysomnography studies have shown that seltorexant shortens latency to persistent sleep and increases total sleep time and sleep efficiency ^[3], and a large randomized, double-blind, active- and placebo-controlled dose-finding trial confirmed improvements in sleep initiation and maintenance across fourteen days with generally good tolerability ^[1]. In major depressive disorder, exploratory and Phase 2b studies have reported antidepressant effects, most pronounced in patients who also have insomnia symptoms, positioning orexin-2 blockade as a novel augmentation strategy ^[2][5]. Medicinal chemistry work has further explored selective orexin-2 antagonist scaffolds and their sleep-promoting properties in animals ^[6].

Seltorexant has been advanced by Janssen and Minerva Neurosciences and, at the time of writing, remains investigational rather than an approved medicine, with Phase 3 evaluation underway for depression with insomnia ^[2]. It is administered orally and is designed around a short half-life so that the wake-suppressing effect is concentrated at night. Its appeal derives from a mechanism that works with the brain's own sleep-wake regulation, offering a targeted alternative to GABAergic hypnotics, together with a clinical signal that it may help mood and sleep at the same time in depressed patients ^[2][5].

⚠️ THE DRUG IS NOT BEING DEVELOPED FOR INSOMNIA, WHICH IS THE OPPOSITE OF HOW IT IS USUALLY DESCRIBED. Of 35 registered trials, only two study primary insomnia disorder, the later of which finished its primary phase in 2019 with no successor since. Every phase 3 trial is in major depressive disorder. Insomnia survives inside that programme only as an entry requirement and as secondary sleep endpoints ^[13].

The insomnia data that does exist is strong. In a 365-person phase 2b trial against both placebo and zolpidem, 20 milligrams cut the time to persistent sleep by 49 percent against placebo on the first night, and 29 percent against zolpidem ^[1]. ⚠️ The more interesting result is at two weeks: seltorexant held its effect while zolpidem's faded, leaving it 28 to 30 percent better than zolpidem on night 13. The 5 milligram dose did nothing.

⚠️ One number in that trial should be reported with its caveat rather than repeated approvingly. Treatment-emergent adverse events occurred in 33.8 percent on seltorexant against 49.3 percent on placebo. A drug cannot plausibly cause fewer adverse events than placebo, and independent commentary has flagged that it needs explaining ^[13]. Four participants discontinued for asymptomatic electrocardiogram findings, all of them older adults, which most summaries omit.

⚠️ IN DEPRESSION, MORE IS WORSE, CONSISTENTLY. Forty milligrams performed worse than twenty in three independent studies: the 40 milligram arm was dropped at an interim analysis in the phase 2b, monotherapy at 20 milligrams beat both 40 and placebo, and the head-to-head against quetiapine found 20 numerically better at weeks 18 and 24 ^[5][11][7]. A mechanism has been proposed: the waking cortisol response fell at 20 milligrams but not 40, and only the 40 milligram arm shortened REM latency and increased light sleep ^[11]. ⚠️ The inverted curve is specific to the antidepressant effect; on sleep endpoints 20 and 40 milligrams are equivalent.

The antidepressant effect is also concentrated in patients who cannot sleep. At six weeks the adjunctive phase 2b missed its primary endpoint overall, and the separation lived almost entirely in the group with baseline insomnia scores of 15 or above ^[5]. Importantly the benefit survived removing the sleep items from the depression scale, so it is not purely an artefact of measuring sleep twice ^[11].

⚠️ No phase 3 trial has been published anywhere. A completed 588-person study has posted registry results, a completed 757-person head-to-head against quetiapine has posted none, and a third was terminated after 212 participants with no reason exposed in the registry. Everything currently citable in the peer-reviewed literature is phase 1 or 2. A network meta-analysis of 170 insomnia trials places it among the agents more effective than placebo and better tolerated than the older hypnotics, while concluding that data on it were too scarce to allow firm conclusions ^[12].

Seltorexant is an investigational selective orexin-2 receptor antagonist that is not approved by regulators, and its full safety profile is still being established in trials. As with sleep-promoting orexin antagonists, the main expected effects are next-day somnolence, headache, and possible impairment of morning alertness, including driving. Its long-term safety and interactions with alcohol and other central nervous system depressants are not fully characterized.

Seltorexant is an investigational selective orexin-2 receptor antagonist and is not marketed, so no approved label interactions section exists; the documented data come from clinical pharmacology studies. It is primarily metabolized by CYP3A4, so co-administration with strong CYP3A4 inhibitors is expected to raise its exposure while CYP3A4 inducers are expected to lower it, as reported in its clinical development program. As a sedating hypnotic, additive next-morning sedation and psychomotor impairment with alcohol and other CNS depressants is the pharmacologically expected concern. Formal interaction profiling remains limited to trial-stage data rather than a finalized regulatory monograph. This is research information, not medical advice.

Checking a whole stack? Run it through interactions + stacks.

Seltorexant, known during development as JNJ-42847922 and MIN-202, was created by Janssen (part of Johnson and Johnson) and advanced in collaboration with Minerva Neurosciences as a selective antagonist of the orexin-2 receptor. Its design rationale was to block the specific orexin receptor subtype most closely tied to arousal and the sleep-wake switch while sparing the orexin-1 receptor, in the hope of achieving focused effects on sleep with good tolerability. The molecule was engineered with a short half-life to limit next-morning grogginess. It has been carried through a series of randomized controlled trials in insomnia and, notably, in major depressive disorder accompanied by insomnia, where the same orexin-2 mechanism was hypothesized to yield mood benefits. It remains an investigational agent in advanced clinical development rather than an approved medicine.

Seltorexant has attracted considerable interest as a more selective member of the orexin antagonist family, distinct from the approved dual antagonists in targeting only the orexin-2 receptor. In insomnia trials it improved measures such as sleep latency and total sleep time and, in one dose-finding study, maintained its benefit through nearly two weeks while the comparator zolpidem lost effect, all with a favorable profile of treatment-emergent adverse events. Perhaps its most compelling feature is early evidence that it may help depression, particularly in patients whose depression is accompanied by significant insomnia, positioning it at an intriguing intersection of sleep and mood. It is only fair to note that it is still investigational and that its ultimate approval and clinical role depend on the full weight of its late-stage trial program.